Riskpilot← Back to searchSign inGet full accessODI MEDICAL AS
ASActiveOrg 914127068Karenslyst Allé 8A, 0278 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20146 employeeswww.odimedical.com
Revenue 2024
NOK 77K
+131% vs 2023
EBITDA margin
-13761.1%
-3% vs 2023
Equity ratio
90.5%
Financial strength
Net profit 2024
NOK -11,7M
+3% vs 2023
| Revenue | NOK 77K | +131% |
| EBITDA | NOK -10,7M | -3% |
| Net profit | NOK -11,7M | +3% |
| Total assets | NOK 34,4M | -14% |
| Equity | NOK 31,2M | -10% |
| Employees | 6 | — |
Legal name
ODI MEDICAL AS
Org number
914127068
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
8. september 2014
Share capital
NOK 209 365
Employees
6 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder alene eller styrets leder alene.
Company purpose
Utvikle og markedsføre ikke-invasive instrumenter, prosesser og systemer for å måle mikrosirkulasjon i menneskekroppen.
Address
Karenslyst Allé 8A, 0278 Oslo
Phone
+4790772157
Email
office@odimedical.com
Website
www.odimedical.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 915 | 3 142 | 480 | 34 | 77 |
| Staff expenses | −4 221 | −4 152 | −4 606 | −5 667 | −6 639 |
| EBITDA | −6 967 | −10 669 | −12 517 | −10 308 | −10 663 |
| Depreciation & amort. | −746 | −912 | −1 376 | −948 | −986 |
| EBIT | −7 713 | −11 581 | −13 893 | −11 256 | −11 649 |
| Net financials | −47 | −29 | −62 | −841 | −53 |
| Profit before tax | −7 760 | −11 610 | −13 955 | −12 096 | −11 702 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −7 760 | −11 610 | −13 955 | −12 096 | −11 702 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 14 132 | 22 488 | 16 323 | 39 931 | 34 443 |
| Equity | 12 431 | 20 324 | 14 173 | 34 810 | 31 179 |
| Long-term debt | 0 | 0 | 0 | 1 870 | 1 124 |
| Short-term debt | 1 701 | 2 165 | 2 149 | 3 250 | 2 140 |
| Total debt | 1 701 | 2 165 | 2 149 | 5 120 | 3 264 |
EBITDA margin
-13761.1%
This company
15.8%
Market median
-87196% vs market
20202024
Equity ratio
90.5%
This company
38.2%
Market median
+137% vs market
20202024
Return on equity
-37.5%
This company
18.4%
Market median
-304% vs market
20202024
Net profit margin
-15102.4%
This company
8.1%
Market median
-186549% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
JU Chief Executive Officer | Chief Executive Officer | 2025 |
YM Chief Executive Officer | Chief Executive Officer | 2021 |
AW Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (1) | ||
SB Chief Executive Officer | Chief Executive Officer | 2021 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 22.56% | 22.56% | 2023 | |
| Individual | 19.04% | 19.04% | 2023 | |
| Company | 9.29% | 9.29% | 2023 | |
| Company | 6.46% | 6.46% | 2023 | |
| Company | 5.12% | 5.12% | 2023 | |
| Individual | 4.81% | 4.81% | 2023 | |
| Individual | 4.81% | 4.81% | 2023 | |
| Individual | 4.81% | 4.81% | 2023 | |
| Individual | 4.81% | 4.81% | 2023 | |
| Individual | 4.81% | 4.81% | 2022 | |
| Company | 3.16% | 3.16% | 2023 | |
| Company | 1.65% | 1.65% | 2023 | |
| Company | 1.06% | 1.06% | 2023 | |
| Individual | 1.01% | 1.01% | 2023 | |
| Individual | 1.01% | 1.01% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ODI MEDICAL AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jørn Ulheim | Chief Executive Officer | 0 companies |
| Yngve Mikkelsen | Chief Executive Officer | 0 companies |
| Anders Wold | Chief Executive Officer | 0 companies |
| Stein Bleivik | Chief Executive Officer | 0 companies |
| Nina Bøyum | Board of Directors | 0 companies |
| Kjetil Dahl | Board of Directors | 0 companies |
| Lars Raastad Holmøy | Board of Directors | 0 companies |
| Tore Engebretsen | Board of Directors | 0 companies |